Summary Immunotherapy with Mycobacterium w (M. w) vaccine was given to 45 patients with multi bacillary (MB) leprosy; 41 similarly classified patients served as controls. All patients received standard multi drug therapy (MDT). Incidence, severity and frequency of type 2 (ENL) reactional episodes were monitored in both groups in a fo llow-up extending up to 4 years. Reactions were seen in fe wer vaccinated (10/37) BL and LL patients than in the control group (12/34). A total of 20 episodes were recorded in the vaccine group as against 29 in the controls, 75% of reactions were mild in vaccinated and 51·72% were mild in the control group patients, and 3 patients in the control group had more than 3 reactional episodes. None of the vaccinated patients showed this. No additional incidence of neuritis were seen among vaccinated individuals during reactional episodes.
Erythema nodosum leprosum (type 2 reaction) affects patients with multi bacillary BL and LL types of leprosy. Over 50% of LL and 25% of BL patients experience type 2 reactions.l There is a sudden development of crops of small, tender, subcutaneous nodules which persist for a few days and then subside. Other clinical fe atures include fe ver, neuritis and polyarthralgia. 2 Histological fe atures consist of 3 distinct changes: I, intense infiltration of neutrophilic granulocytes within the lepromatous macrophage granuloma; 2, abundant presence of fragmented and granular bacilli; and 3, oedema of endothelium of vessel walls with granulocyte infiltration and local vasculitis. 3 The aetiopathogenesis of this symptom complex is the fo rmation of immune complexes which are deposited in selective tissue sites. These complexes consist of mycobacterial antigens, IgG or IgM antibodies and complement. 4 It has been postulated that in ENL, there is an imbalance of immunoregulatory T-cell subsets. This is manifested as an increased ratio of helper (CD4 + ) to suppressor/cytotoxic (CD8 + ) T cells in blood. 5 Decrease in CD8 + T cells may favour fo rmation and deposition of immune complexes. 6 Mycobacterium w (M. w) was selected from a panel of 16 mycobacteria on the basis of its immunological potentials.? It is a nonpathogenic, atypical, rapid growing mycobacter ium. 8 It has undergone Phase I trials in Calcutta9 and is currently in Phase III trials in Delhi and large-scale field trials in District Kanpur Dehat of Uttar Pradesh, State of North India. Results on the I st series of multibacillary patients have been reported and have evidenced some immunotherapeutic benefits of combining this vaccine with standard MDT. The vaccine effectively brought about: 1, rapid BI fall; 2, fa ster clinical improvement; 3, lepromin conversion; and 4, histological upgrading. Due to a rapid overall improvement, treatment duration in vaccinated patients was shorter and more patients could be released from treatment (RFT) within the stipulated 2 treatment years. 1 0 -13
This report gives the incidence, frequency and severity ofENL (type 2) reactions in 86 patients who have been fo llowed up for up to 4 years--45 have received MDT + M. w vaccine (vaccine group) and 41 of them are included in a group receiving MDT + micro nized starch as placebo.
Materials and Methods
Patients inducted in this study form part of the large-scale Phase III immunotherapeutic trials being conducted at the Urban Leprosy Centres (ULCs) of Safdarjung and Dr Ram Manohar Lohia Hospitals of New Delhi.
Patients fa lling in a, BB, BL and LL spectrum of disease (Ridley-Jopling Scale); b, showing evidence of bacilli in slit-skin smears; c, negative in their Mitsuda reaction to lepromin-A; and d, having histological fe atures ofBB, BL or LL type disease are enrolled. Standard MDT as recommended by NLEP ofIndia was given to all those inducted. 14 Half the patients, in addition, received intradermally M.w vaccine (containing I x 109 killed bacilli per dose as the 1st dose and 5 x 108 killed bacilli as the 2nd and subsequent doses every 3 months up to a maximum of 8 doses). The other half of the patients received a placebo injection of micronized starch at the same time intervals. Allotment of patients into the vaccine and control groups was done in a randomized manner according to a code supplied to the clinician.
Evaluation of reactions
A detailed history of the patient experiencing any previous reactions (type, severity, frequency and duration) was taken at the time of enrollment. A reaction proforma was filled for each reactional episode during the 2 or more years of treatment and subsequent fo llow-up. This proforma included eliciting a history of fe ver, joint pains, epistaxis, conjunctivitis, pedal oedema, lymphadenopathy and epididymo-orchitis. Examination of skin fo r ENL lesions, ulceration or desquamation was looked fo r. Pain/tenderness of peripheral nerves, recent development of sensory and motor deformities were especially elicited. Grading of reaction was as 'mild', 'moderate' or 'severe'.15 Treatment details during reactional episode were recorded separately on the proforma. Mild reaction was managed with rest and nonsteroidal anti-inflammatory drugs (NSAID). Moderate cases were managed on an outdoor basis on oral steroids and NSAID. Severe cases were hospitalized and oral steroids were given.
Results
Of the 86 patients enrolled in the study, 45 were inducted in the vaccine group and 41 in the control group (Table I) .
A total of II patients in the vaccine group had a previous history of Type 2 reaction and 10 of these showed subsequent reactions during the 2 years or more of chemoimmu notherapy; I patient with a previous history of2 reactional episodes before treatment had no ENL during treatment. In the control group, 8 patients had a previous history ofENL. During 2 or more years of treatment with MDT, 12 patients had reactions. Thus, 4 patients with no previous history of ENL had first-time reactions after treatment in this group.
During the course of 2 or more years of fo llow-up, 20 reactional episodes in 1 0 (out of 37) BL and LL patients were recorded in the vaccine group ( Table 2 ). The number of episodes were higher in the control group where 29 were seen in 12 (out of 34) BL and LL patients.
With regard to the onset of Type 2 reactions (Table 3) , in the vaccine group, reactions were seen throughout 2 or more years, although most occurred within the I st year (13 out (10/20) Figures in parentheses give the number of patients experiencing reactional episodes by total number of patients; II patients in the vaccine group and 8 patients in the control group had a history of reaction prior to initiation of therapy. With reference to severity of reactional episodes, reactions were mild in 15 out of 20 episodes in the vaccine group and 15 out of 29 in the control group; 14 reactions were moderate to severe in the control group (Table 3) .
Frequency of reactional episodes in vaccine and control groups were: vaccine, 3 patients (30%) once, 4 (40%) twice and 3 (30%) thrice; and control, 3 (25%) once, 4 (33%) twice, 2 (16, 6%) thrice and 3 patients (25%) more than 3 episodes (Table 4) .
In the vaccine group 5 patients (2-BL, 3-LL) had neuritis during episodes of ENL. This resulted in a left ulnar claw in a BL patient and a bilateral claw in an LL patient. In the control group neuritis was seen in 6 patients (2-BL, 4-LL); I BL patient had a left ulnar claw and facial palsy.
BI CHANGES
Changes in the BI of patients in the study are given in Table 5 . The fall in LL patients receiving the vaccine was from 3·90 (±0·27 SEM) to 0·92 (±0·28 SEM) after 2 years of immunochemotherapy, whereas in the control group corresponding values were 3·67 (±0·25 SEM) to 1·78 (±0·29 SEM). In BL type leprosy the fall over 2 years was 2·51 (±0·29 SEM) to 0·02 (±0·01 SEM) in the vaccine group and 2·02 (±0·30 SEM) to 0·63 (±0·20 SEM) in the control group.
Discussion
Erythema nodosum leprosum (ENL) is triggered when there is an abundance of fr agmented or granular bacilli in tissues. These 'nonviable' bacillary fo rms act as antigens and in the presence of precipitating antibodies and complement factors result in formation of immune complexes.4 Data regarding the incidence of Type 2 (ENL) reactions with use of MDT is scarce. In 2 studies, MDT seems to have caused no worsening or development of fresh reactions over monotherapy (in a 2-year fo llow-up). 1 6.1 7 In another study in Madras, 62 out of 177 (35%) BL or LL patients showed evidence of Type 2 reactions. 1 8 Some of the patients in this study showed reactions even up to 60 months of fo llow-up. In our experience, the incidence of reactions in the control group (receiving MDT alone) BL and LL patients was 12/34 (35 , 29%), which is quite comparable with reports in the literature. After immunization with M. w vaccine, patients had accelerated bacteriological clearance. The fa ll at the end of2 years of treatment was statistically significant in both LL (p < 0'06) and BL (p < 0'003) vaccine group patients. In fact, the BI after 12 months of treatment in vaccine group BL patients was lower than that achieved by control group patients at 24 months (Table 5) . Several earlier reports have also documented a rapid clearance of bacilli from slit-skin smear sites'9, 2 0 and from biopsy tissues'3 in M.w vaccinated patients. Some patients with high BI of 5-6 have shown clearance of AFB within 18-24 months. 2 0 BI fa ll per 12 treatment months in LL patients in the vaccine group was reported to be 1·84 (± 0·18 SEM) compared to 0·98 (± 0 , 11 SEM) in the control group , In BL patients, it was 1·64 (± 0,20 SEM) (vaccine group) and 0·63 (± 0· 14 SEM) (control group). 1 9 This rapid clearance of AFB from the body may explain: I, less incidence of reactions in the vaccine vs control group (10 patients/20 episodes vs 12 patients/29 episodes); and 2, most reactional episodes occurring early in the vaccine group (13 out of20 in the I st year (65%), 17 out of 20 by the 2nd year (85%) and only 3 episodes beyond 2 years (15%)) , In the control group figures were 13/29 (44,82%) in the 1 st year, 23/29 (79·31 %) by the 2nd year and 6 episodes beyond 2 years (20, 6%). The reactions were also less severe in the vaccine group; 15 of20 reactions (75%) were mild, 4 (20%) were moderate and only I severe (5%). In contrast, patients in the control group had 15 (5 1 '72%) mild, 11 (37%) moderate and 3 (10,3%) severe reactional episodes , Frequency of reactional episodes was quite compar able in the 2 groups. The difference was that in the control group 3 patients (25%) had more than 3 episodes, which was not seen among vaccinated patients. Statistical analysis of data using test of proportions showed insignificant differences between the vaccine and control groups fo r incidence of reactional episodes (z = 0'7525), early occurrence of reactions (within the 1st year) (z =I·39) and being milder in the vaccinated patients (z = 1·6435). As can be seen by the 'z' values the differences were at the margin/border of being significant. One reason for this could be the small sample size.
However, analysis based on a 95% confidence interval 2 1 brought out distinct differences between the 2 groups more evocatively (Table 6 ). Confidence intervals indicated that at best the vaccine was a great advantage (29, 8; 47·8; 49,57%) and at worst a slight disadvantage (-13'2; -7'5; -3%) (see Table 6 ).
Immunotherapy wi th M. vaccae in patients with chronic repeated ENL has shown resolution of reaction some 2-3 months later in about half the cases in an on-going study. 22 Using immunotherapy with killed M. leprae and live BCG, Convit et al. 2 3 reported that vaccination coincided with the disappearance of ENL lesions in some patients.
When using ICRC vaccine, Deo et al. 2 4 reported that half the vaccinated LL patients, with BI 3-5, developed ENL reactions 2-6 weeks postvaccination. These patients had no previous history of ENL. ENL in these patients, according to the authors, was precipitated by either the presence of appropriate antigens of ICRC bacillus or large quantities of antigens released through breakdown of M. leprae upon vaccination. 24 Effects of immunotherapeutic cytokines gamma interfe ron and interleukin 2 on ENL reactions have not been reported in the literature.
An important observation was that the use of M.w vaccine did not precipitate any additional incidence of neuritis or deformity during the course of Type 2 reactions. This has also been evidenced histologically where vaccinated patients did not show evidence of an increase in dermal nerve twig inflammation. 13 Experiences using immunotherapeutic candidate vaccines, 1, M.leprae and BCG, and 2, M. vaccae indicate that there is a decrease in incidence of type 2 reactions postvaccination. This is similar to our experience using M,w vaccine, where a decrease in incidence, frequency and severity of reactions have been recorded. Contrary to these findings are the results with ICRC vaccine (where half of LL patients with BI 3-5 had ENL reactions postvaccination). Based on our experience and that of others, it appears that any immunotherapeutic agent capable of inducing rapid bacterial clearance should also secondarily decrease the incidence of Type 2 reactions. Resume L'immunotherapie par Ie vaccin Mycobacterium w (M.w) a ete administree a 45 patients atteints de lepre multibacillaire; 41 patients classes de fa.yon similaire ont servi de temoins. Tous les patients ont re.yu la therapeutique multidrogue standard (MDT). L'incidence, la severite et la frequence des episodes reactionnels de type 2 (ENL) ont ete sui vis dans ces 2 groupes pendant une periode qui a dure jusqu'a 4 ans. On a observe des reactions chez un plus petit nombre de patients BL et LL vaccines (l 0/37) que dans Ie groupe temoin (12/24) . Au total, 20 episodes ont ete enregistres dans Ie groupe des vaccines contre 29 dans Ie groupe des temoins, 75% des reactions ont ete fa ibles dans Ie groupe des vaccines et 51,72% ont ete fa ibles dans celui des temoins, et 3 patients du groupe des temoins ont eu plus de 3 episodes reaction nels, ce que l'on n'a observe chez aucun des patients vaccines. Aucune incidence supplementaire de nevrite n'a ele observee parmi les individus vaccines au cours des episodes reaction nels.
La inmunoterapia con vacuna My cobacterium-w reduce la incidencia y severidad de las reacciones (ENL) de tipo 2
